European Association For The Study Of The Liver
BERLIN, April 2, 2011 - Thalidomide has shown potential to be used as the first
adjuvant therapy for hepatocellular carcinoma (HCC), according to data
presented at the International Liver Congress(TM) 2011.[1]
To view the Multimedia News Release, please click:
multivu.prnewswire.com/mnr/prne/easl/48894/
A new study found thalidomide gave HCC patients who'd
undergone grossly curative resection - surgical removal of the cancerous part
of the liver - double the two-year disease free survival rate (65%) compared
to placebo (33%).
BERLIN, April 1, 2011 - Findings from two new studies presented today at the
International Liver Congress(TM) confirm that there are options for
clinicians to expand the pool of liver grafts for use in patients with
liver disease.
BERLIN, April 1, 2011 - Early data from phase I trials of an HCV vaccine presented
today at the International Liver Congress(TM) show encouraging results, with
high immunogenicity and good safety profile.(1),(2)
To view the Multimedia News Release, please click:
multivu.prnewswire.com/mnr/prne/easl/48894/
In the first study[1], a therapeutic T-cell vaccine, based on
novel adenoviral vectors was used on a small population of treatment naive
patients with chronic genotype 1 HCV infection.
BERLIN, March 31, 2011 - New data presented today at the International Liver Congress(TM) confirm
the antiviral activity of fluvastatin - commonly used as a
cholesterol-lowering treatment - in patients with chronic hepatitis C
(HCV).[1]
To view the Multimedia News Release, please click:
multivu.prnewswire.com/mnr/prne/easl/48894/
Patients had improved early and sustained virological response (EVR and
SVR) when treated with the current standard of care - pegylated
Interferon-alpha and ribavirin (PegIFNalpha/RBV) - and fluvastatin.
ATHENS, December 10, 2010 - Europe is failing to deal with the life-threatening effects of
excessive and regular alcohol consumption on its citizens' health.
